Mathilde Puel, Kenza Rwayane, Paula Vieira Martins, Marwa Chbihi, Frédéric Rieux-Laucat, Jérémie Rosain, Eric Jeziorski, Bertrand Boisson, Jean-Laurent Casanova, Véronique Frémeaux-Bacchi, Carine El Sissy
{"title":"Two New Kindreds with Complete Factor D Deficiency","authors":"Mathilde Puel, Kenza Rwayane, Paula Vieira Martins, Marwa Chbihi, Frédéric Rieux-Laucat, Jérémie Rosain, Eric Jeziorski, Bertrand Boisson, Jean-Laurent Casanova, Véronique Frémeaux-Bacchi, Carine El Sissy","doi":"10.1002/eji.202451536","DOIUrl":null,"url":null,"abstract":"<p>Inborn deficiencies of the alternative pathway (AP) of the complement system have been associated with life-threatening infections, mainly by encapsulated bacteria. Complete factor D (FD) deficiencies have been reported in only seven families in the literature. We report two new cases of biochemically and genetically confirmed complete FD deficiency, including the first in a Down syndrome patient. The index cases respectively suffered from severe <i>H. influenza</i> and <i>N. meningitidis</i> infections. Their FD activity was undetectable but was restored by adding recombinant human FD. FD levels were undetectable in the plasma of both patients using ELISA. Genetic analysis of the <i>CFD</i> gene identified a homozygous missense variant p.M40R in one patient, and compound heterozygous variants—a nonsense mutation p.Cys148* and a splice site variant c.212+2T>G—in the other. Patients with Down syndrome are more susceptible to infections, but this case highlights the importance of investigating the complement system, particularly the AP, even in those with Down syndrome or other secondary immune deficiencies. A familial study should follow if a congenital deficiency is found. The natural history of patients with inherited complete FD deficiency underscores the necessity of preventive measures against encapsulated bacteria for those receiving therapeutic MASP-3 or FD inhibitors.</p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"55 3","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202451536","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/eji.202451536","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Inborn deficiencies of the alternative pathway (AP) of the complement system have been associated with life-threatening infections, mainly by encapsulated bacteria. Complete factor D (FD) deficiencies have been reported in only seven families in the literature. We report two new cases of biochemically and genetically confirmed complete FD deficiency, including the first in a Down syndrome patient. The index cases respectively suffered from severe H. influenza and N. meningitidis infections. Their FD activity was undetectable but was restored by adding recombinant human FD. FD levels were undetectable in the plasma of both patients using ELISA. Genetic analysis of the CFD gene identified a homozygous missense variant p.M40R in one patient, and compound heterozygous variants—a nonsense mutation p.Cys148* and a splice site variant c.212+2T>G—in the other. Patients with Down syndrome are more susceptible to infections, but this case highlights the importance of investigating the complement system, particularly the AP, even in those with Down syndrome or other secondary immune deficiencies. A familial study should follow if a congenital deficiency is found. The natural history of patients with inherited complete FD deficiency underscores the necessity of preventive measures against encapsulated bacteria for those receiving therapeutic MASP-3 or FD inhibitors.
期刊介绍:
The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.